Cancer Dx test maker Veracyte launches successful IPO

A month after filing IPO plans, molecular diagnostics test maker Veracyte ($VCYT) finally went public on Oct. 30. The South San Francisco company said it sold 5 million shares of common stock for $13 each and pulled in $65 million. That came in at the low end of Veracyte's range. The company initially said it would offer 4.7 million shares priced between $13 and $15 each. Veracyte, a 2013 Fierce 15 winner, also granted the underwriters a 30-day option to snatch up an additional 750,000 shares of common stock at the initial public offering price to cover any overallotments. Veracyte's Afirma test combines a specialized cytopathology assessment and gene-expression test to determine whether a thyroid nodule is benign or cancerous. Story